At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
IMC-1121B +2 morebiological
Likely dose
IMC-1121B 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer
In Brief
A Phase 2 clinical trial evaluating IMC-1121B, Moxifloxacin, and 1 other intervention for Cancer and Solid Tumor. Completed, enrolled 68 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionApr 2010
Study CompletionMay 2014
TodayJul 2026
First PostedNov 23, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2010
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.6 years ago
Interventions
IMC-1121Bbiological
IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
Moxifloxacindrug
Administered orally
Diphenhydraminedrug
Administered IV